• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

The Challenging Search for BTK Inhibitors

by Bellbrook Labs / Tuesday, 27 December 2022 / Published in Emerging Targets, HTS Assays, Innate Immunity
BTK's Involved in Systemic lupus erythematosus

Bruton’s Tyrosine Kinase (BTK) is a 76kDa non-receptor Tec kinase that plays numerous diverse roles in B-cell development, immunity, autoimmunity, infection, and cancer. From stem to stern, it consists of an N-terminal plekstrin homology (PH) domain, a TEC homology (TH) domain, two SRC homology (SH2 and SH3) domains, and a C-terminal kinase domain. Unlike SRC, BTK is a cytoplasmic protein and only present at interior cell membranes upon recruitment.1

Structure & Corresponding Function

BTK’s PH domain binds phosphatidylinositol lipids within biological membranes, phospholipase C gamma 2 (PLCg2), and phosphatidylinositol (3,4,5)-triphosphate (PIP3). In it’s inactive state, the TH domain binds the activation loop face of the kinase domain to sterically hinder the lipid-binding pocket of the PH domain. Likewise, under conditions of inactivation, the SH2 and SH3 domains bind the distal side of the kinase domain to restrain access to its active site. Once at the cell membrane, BTK can become activated by the interaction with SRC kinases and phosphorylation occurs at position 551 of the kinase. This can also occur through interaction with a SYK kinase. The SH2 domain and kinase domain together form an allosteric interface, critical for BTK’s activation.1

When BTK’s PH domain binds the membrane, subsequent PIP3 interaction induces BTK to phosphorylate PLCg2. Phosphorylated PLCg2 hydrolyzes PIP2 into two second messengers, inositol triphosphate (IP3) and diacylglycerol (DAG), that modulate the activity of downstream protein signaling.1

BTK’s Role in Immunity

BTK mediates receptor signaling in several crucial areas. Antigen stimulated B-cell receptors utilize BTK to transmit their activation, leading to B-cell differentiation and proliferation. Additionally, BTK interacts with Toll-like receptors to link adaptive and innate immunity. SDF-1 activates BTK in response to chemokine signalling.2

In immune complex-driven activation, BTK affects immunity by increasing Treg/CD4+ ratios, thereby, having an immunosuppressive effect on T-cells. BTK is also involved in Mac-1 activation, recruiting neutrophils to sites of inflammation. In addition, BTK is a positive regulator of the NLRP3 inflammasome due to its pivotal role in NLRP3 tyrosine phosphorylation and IL-1beta release.2

In the area of pathogen defense, BTK activates calcineurin-NFAT in macrophages to repel fungal invaders. In response to bacterial infection, it mediates SKAP-2 dependent ROS activation in neutrophils to enhance pathogen clearance. When macrophage TLRs recognize single-stranded viral RNA, they initiate signaling through BTK-dependent activation of NF-κB. This triggers the production of multiple inflammatory cytokines and chemokines, as well as phagocytosis.2

Therapeutic Complexities

Unfortunately, increased levels of BTK support autoantibody production, driving autoimmune disease. Systemic lupus erythematosus (SLE) is characterized by the secretion of autoantibodies. SLE’s autoreactive B-cells exhibit increased levels of BTK expression. Additionally, rheumatoid arthritis (RA) is characterized by autoantibodies that cause chronic inflammation and joint pain. B-cell dysregulation via BCR signaling drives the production of autoantibodies and inflammatory cytokines that provoke and perpetuate RA. In multiple sclerosis, inhibition of BTK has prevented microglia from engulfing and demyelinating myelin sheaths.2

Due to its key role in B-cell proliferation, aberrantly upregulated BTK is a prime driver of several lymphoproliferative disorders: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, and Diffuse Large B-cell Lymphoma.2

Mutations in BTK’s domains are the source of many disease manifestations and, of late, the target of many therapeutics. Due to the multifunctional, multisystem interactions of BTK, domain specific inhibitors have their advantages as well as their off-target effects on other Tec kinases. Specific first- and second-generation inhibitors have impacted native and adaptive immune functions. Additionally, cross inhibition of other proteins bearing Tec domains has led to increased bleeding risk. Resistance has also become an issue.3 Recent work even suggests that different isoforms may be key drivers in epithelial cancers.4 

The search for effective, low side effect inhibitors remains a challenge.

References
1. Kueffer LE, Joseph RE and Andreotti AH (2021) Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK. Front. Cell Dev. Biol. 9:655489. https://doi.org/10.3389/fcell.2021.655489
2. McDonald, C, Xanthopoulos, C, Kostareli, E. The role of Bruton’s tyrosine kinase in the immune system and disease. Immunology. 2021; 164: 722– 736. https://doi.org/10.1111/imm.13416
3. Arneson LC, Carroll KJ, Ruderman EM. Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis. Immunotargets Ther. 2021 Aug 28;10:333-342. https://doi.org/10.2147/itt.s288550.
4. Wang X, Kokabee L, Kokabee M and Conklin DS (2021) Bruton’s Tyrosine Kinase and Its Isoforms in Cancer. Front. Cell Dev. Biol. 9:668996. https://doi.org/10.3389/fcell.2021.668996

Tagged under: Autoimmune Disease, BTK, Innate Immunity, kinase assay

What you can read next

Info book on cancer and RAFK1's relation
RAF1 & Immunity: A Future Model For Cancer Research?
Transcreener ADP Assay Aids in Discovery of RIPK2 Inhibitors for Autoinflammation
Helicases Used in Innate Immunity
Helicases as Powerful Tools in Innate Immunity

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...
  • SIRT2 Affects Neurodegenerative Diseases

    SIRT2 Isoforms in Neurodegenerative Diseases & Cancer

    Silent information regulator type 2 (Sirtuin 2 ...
  • Patient With WRN Helicase Syndrome

    Can WRN Helicase Inhibitors Treat MSI-H Cancers?

    Over 100 years ago, Otto Werner first character...
  • NSP16 Target for COVID-19 Therapeutics

    NSP16 Shows Promise for Anti-Viral Therapeutics

    SARS-CoV-2 virus (Covid-19) possesses one of th...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP